A novel liposomal Clodronate depletes tumor-associated macrophages in primary and metastatic melanoma: Anti-angiogenic and anti-tumor effects

J Control Release. 2016 Feb 10:223:165-177. doi: 10.1016/j.jconrel.2015.12.037. Epub 2015 Dec 29.
No abstract available

Keywords: Adjuvant therapy; Liposomal Clodronate; Melanoma; TAMs.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Antineoplastic Agents* / administration & dosage
  • Antineoplastic Agents* / chemistry
  • Antineoplastic Agents* / pharmacology
  • Antineoplastic Agents* / therapeutic use
  • Apoptosis / drug effects
  • Cell Line
  • Cell Proliferation / drug effects
  • Cell Survival / drug effects
  • Clodronic Acid* / administration & dosage
  • Clodronic Acid* / chemistry
  • Clodronic Acid* / pharmacology
  • Clodronic Acid* / therapeutic use
  • Cytokines / immunology
  • Fatty Acids, Monounsaturated / chemistry
  • Female
  • Fibroblasts / drug effects
  • Humans
  • Liposomes
  • Liver / drug effects
  • Liver / immunology
  • Macrophages / drug effects*
  • Macrophages / immunology
  • Melanoma, Experimental / drug therapy*
  • Melanoma, Experimental / immunology
  • Melanoma, Experimental / pathology
  • Mice, Transgenic
  • Quaternary Ammonium Compounds / chemistry
  • Spleen / drug effects
  • Spleen / immunology
  • Tumor Burden / drug effects

Substances

  • Antineoplastic Agents
  • Cytokines
  • Fatty Acids, Monounsaturated
  • Liposomes
  • Quaternary Ammonium Compounds
  • Clodronic Acid
  • 1,2-dioleoyloxy-3-(trimethylammonium)propane